Select a medication above to begin.
astragalus (Astragalus spp.)
common name
Entire Monograph
Reported Uses
- NOTE: see Herb & Supplement Effectiveness Rating Definitions table
- allergic rhinitis [Insufficient Evidence]
- amenorrhea [Insufficient Evidence]
- anemia, chemo-related [Insufficient Evidence]
- angina [Insufficient Evidence]
- anthracycline-induced cardiotoxicity [Insufficient Evidence]
- aplastic anemia [Insufficient Evidence]
- asthma [Insufficient Evidence]
- beta-thalassemia [Insufficient Evidence]
- breast CA [Insufficient Evidence]
- cervical CA [Insufficient Evidence]
- chronic fatigue syndrome [Insufficient Evidence]
- cirrhosis [Insufficient Evidence]
- CKD [Insufficient Evidence]
- colorectal CA [Insufficient Evidence]
- COPD [Insufficient Evidence]
- diabetes mellitus [Insufficient Evidence]
- diabetic nephropathy [Insufficient Evidence]
- diabetic neuropathy [Insufficient Evidence]
- diabetic retinopathy [Insufficient Evidence]
- diarrhea, chemo-related [Insufficient Evidence]
- fatigue, chemo-related [Insufficient Evidence]
- fibromyalgia [Insufficient Evidence]
- gastric CA [Insufficient Evidence]
- hearing loss [Insufficient Evidence]
- heart failure [Insufficient Evidence]
- hepatitis B [Insufficient Evidence]
- HIV/AIDS [Insufficient Evidence]
- leukopenia, chemo-related [Insufficient Evidence]
- IgA nephropathy [Insufficient Evidence]
- lung CA [Insufficient Evidence]
- membranous nephropathy [Insufficient Evidence]
- menopausal symptoms [Insufficient Evidence]
- MI [Insufficient Evidence]
- myocarditis [Insufficient Evidence]
- nausea/vomiting, chemo-related [Insufficient Evidence]
- nephrotoxicity, chemo-related [Insufficient Evidence]
- nephrotic syndrome [Insufficient Evidence]
- obesity [Insufficient Evidence]
- post-stroke fatigue [Insufficient Evidence]
- SLE [Insufficient Evidence]
- tinnitus [Insufficient Evidence]
- URI [Insufficient Evidence]
- UTI [Insufficient Evidence]
- wound healing [Insufficient Evidence]
Reported Doses
Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely
Effectiveness Ratings
- [see Herb & Supplement Effectiveness Rating Definitions table]
allergic rhinitis
- [Insufficient Evidence]
- Dose: 160 mg PO bid; Info: standardized to 40% polysaccharides
amenorrhea
- [Insufficient Evidence]
- Dose: 30 g/day PO divided bid
angina
- [Insufficient Evidence]
- Dose: 20 g PO tid
anthracycline-induced cardiotoxicity
- [Insufficient Evidence]
- Dose: 500 mg IV qd x14 days
aplastic anemia
- [Insufficient Evidence]
- Dose: 80-120 g IV qd x15 days; Info: given at 7-10 day intervals for at least 4mo in patients 15 yo and older
chronic fatigue syndrome
- [Insufficient Evidence]
- Dose: 30 g/day PO divided bid
CKD
- [Insufficient Evidence]
- Dose: 15 g PO qd; Info: used with standard tx
diabetes mellitus, type 2
- [Insufficient Evidence]
- Dose: 10-60 g PO qd; Alt: 40-80 g IV qd; Info: used with or without metformin
diarrhea, chemo-related
- [Insufficient Evidence]
- Dose: 40 g IV qd x21 days/cycle
fatigue, chemo-related
- [Insufficient Evidence]
- Dose: 500 mg IV 3x/wk x4wk/cycle
hearing loss
- [Insufficient Evidence]
- Dose: 1 g/kg/dose IV qd x10 days
heart failure
- [Insufficient Evidence]
- Dose: 30 g PO bid; Alt: 2.25-7.5 g PO bid; 60 g IV qd x20 days; Info: used with or without conventional tx
membranous nephropathy
- [Insufficient Evidence]
- Dose: 20-90 g PO qd; Info: used with conventional tx
menopausal symptoms
- [Insufficient Evidence]
- Dose: 15-30 g PO qd
myocarditis
- [Insufficient Evidence]
- Dose: 8 g IM qd x3-4mo; Alt: 40 g IV qd x2wk
nausea/vomiting, chemo-related
- [Insufficient Evidence]
- Dose: 40 g IV qd x21 days/cycle
nephrotic syndrome, peds patients
- [Insufficient Evidence]
- Dose: 7.5 g PO bid in patients <3 yo; 10 g PO bid in patients 3-6 yo; 15 g PO bid in patients 6 yo and older
post-stroke fatigue
- [Insufficient Evidence]
- Dose: 2.8 g PO tid
SLE
- [Insufficient Evidence]
- Dose: 40 g IV qd x12 days/mo x3mo; Info: used with corticosteroids and cyclophosphamide 0.8 g IV qmo
tinnitus
- [Insufficient Evidence]
- Dose: 1 g/kg/dose IV qd x10 days
UTI
- [Insufficient Evidence]
- Dose: 100 mg PO bid x5 days; Info: for use in female patients 18 yo and older
Copyright © 2026. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.